RedHill Biopharma Ltd – (RDHL) Rating Increased to Hold at Zacks Investment Research
RedHill Biopharma Ltd – (NASDAQ:RDHL) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued to investors on Wednesday.
According to Zacks, “RedHill Biopharma focuses on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for gastrointestinal and inflammatory diseases, including cancer. RedHill’s proprietary pipeline includes: RHB-105 – a combination therapy for H.pylori infection; RHB-104 – a combination therapy for Crohn’s disease and multiple sclerosis; BEKINDA – a once-daily oral formulation of ondansetron for acute gastroenteritis and IBS-D; RHB-106 – an encapsulated formulation for bowel preparation licensed to Salix Pharmaceuticals; YELIVA – an orally-administered first-in-class SK2 selective inhibitor targeting oncology, inflammatory and gastrointestinal indications; MESUPRON – a uPA inhibitor targeting gastrointestinal and other solid tumors; RP101 – currently subject to an option-to-acquire, Hsp27 inhibitor targeting gastrointestinal cancers; RIZAPORT – an oral thin film formulation of rizatriptan for acute migraines. “
Separately, FBR & Co reaffirmed a “buy” rating on shares of RedHill Biopharma Ltd – in a report on Friday, September 9th. One analyst has rated the stock with a hold rating and six have given a buy rating to the stock. The company has an average rating of “Buy” and an average price target of $26.00.
Shares of RedHill Biopharma Ltd – (NASDAQ:RDHL) opened at 14.69 on Wednesday. The company has a 50-day moving average of $15.00 and a 200 day moving average of $12.66. The stock’s market cap is $187.06 million. RedHill Biopharma Ltd – has a one year low of $8.10 and a one year high of $16.54.
RedHill Biopharma Ltd – (NASDAQ:RDHL) last posted its quarterly earnings data on Wednesday, July 27th. The company reported ($0.06) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.58) by $0.52. On average, analysts predict that RedHill Biopharma Ltd – will post ($2.06) earnings per share for the current year.
Several institutional investors have recently bought and sold shares of RDHL. Ingalls & Snyder LLC purchased a new stake in RedHill Biopharma Ltd – during the second quarter valued at about $451,000. Royal Bank of Canada boosted its stake in RedHill Biopharma Ltd – by 0.9% in the first quarter. Royal Bank of Canada now owns 21,167 shares of the company’s stock valued at $259,000 after buying an additional 191 shares during the last quarter. Oppenheimer & Co. Inc. purchased a new stake in RedHill Biopharma Ltd – during the second quarter valued at about $142,000. Finally, Van ECK Associates Corp boosted its stake in RedHill Biopharma Ltd – by 1.5% in the second quarter. Van ECK Associates Corp now owns 9,623 shares of the company’s stock valued at $105,000 after buying an additional 138 shares during the last quarter.
About RedHill Biopharma Ltd –
Receive News & Stock Ratings for RedHill Biopharma Ltd - Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RedHill Biopharma Ltd - and related stocks with our FREE daily email newsletter.